On the other side, our results on the GnRH antagonist protocol were consistent with the results of the prospective study of Afiat et al. [7], which could not detect any significant differences in the number of MII oocytes and MI oocytes between PCOS (n = 50) and controls (n = 50) that treated with GnRH antagonist protocol. The gene discussed is GNRH1; the disease is polycystic ovary syndrome.